20xx年醫(yī)學專題—呼吸系統(tǒng)pkpd-劉世霆(編輯修改稿)
2024-11-05 06:35 本頁面
【文章內容簡介】 meropenem. By use of a microinfusion pump the in situ probes were constantly perfused with Ringer’s solution at a flow rate of 1.5 l/min. Microdialysis was started approximately 30 min after probe insertion, and the patients were monitored on the intensive care unit. For calibration, prior to the systemic administration of the study drug, the probes were perfused for 20 min with a solution of the drug, resulting in diffusion from the lumen into the tissue.,第二十三頁，共五十三頁。,美洛培南在肺內的藥代和藥效(y224。o xi224。o),After a sufficient washout period for the system, meropenem was administered i.v. at a dose of 1 g over 20 min. Sampling of dialysates and venous blood was performed at 20min intervals for a period of 8 h. Blood samples were collected in plastic tubes and were immediately centrifuged at 1,600 g for 5 min. Serum and dialysate samples were shock frozen and stored over liquid nitrogen until analysis. Meropenem was assayed by using highpressure liquid chromatography method with a limit of detection of 1mg/liter,第二十四頁，共五十三頁。,Pharmacokinetic parameters for meropenem (noncompartmental analysis) in serum, lung interstitial fluid,a Parameters were measured after the i.v. administration of meropenem at 1 g to seven patients with sepsis and undergoing lateral thoracotomy for pneumonia ormetapneumonic pleural empyema. Except for Tmax, results are expressed as mean and standard deviation. b At the end of the infusion.,第二十五頁，共五十三頁。,美洛培南在肺內的藥代和藥效(y224。o xi224。o),In the present study, meropenem was administered at a dose of 1 g every 8 h, as recommended by the manufacturer. At this dosage, sufficient concentrations of unbound meropenem were found in the interstitial space fluid of infected lung tissue in patients with metapneumonic empyema. The concentrations of meropenem in tissue were maintained above the MIC90 threshold for many clinically relevant pathogens, including S. aureus, S. pneumoniae, P. aeruginosa, E. aerogenes, and K. pneumoniae, for up to 6 h (i.e., 80% of the dosing interval).,第二十六頁，共五十三頁。,利奈唑胺多劑口服(kǒuf)后的藥代動力學和組織穿透性,第二十七頁，共五十三頁。,利奈唑胺多劑口服(kǒuf)后的藥代動力學和組織穿透性,利奈唑胺屬于一類新的抗菌藥——噁唑烷酮類 通過抑制蛋白質合成的起始階段起抗菌作用 在體外和體內對革蘭陽性菌具有良好的抗菌作用，包括耐藥菌株 目的：評價在600mg多劑口服后，利奈唑胺的藥代動力學和組織穿透性 采用(cǎiy242。ng)水泡液模擬炎癥滲出液,THEKLI GEE，et al, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,2001,45(6),18431846,第二十八頁，共五十三頁。,材料(c225。ili224。o)與方法,受試者：8名，平均年齡29.6177。8.7歲，平均(p237。ngjūn)體重78.6177。7.1 kg，平均身高180.4177。14.1 cm，1名受試者因發(fā)熱推出研究，實際參加者7名,受試者7名,利奈唑胺 600㎎/12h, 共5劑,給藥前及 末次給藥 后取血標本(biāoběn),取標本：給藥前及末次給藥后0.5，1，1.5，2，3，4，6，8，10，和12 h 取血標本，同時取水泡液,THEKLI GEE，et al, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,2001,45(6),18431846,第二十九頁，共五十三頁。,,,,,水泡液中藥物(y224。ow249。)濃度檢測,血中藥物濃度(n243。ngd249。)檢測,藥
公司管理相關推薦
鄂ICP備17016276號-1